Provider review, September 2026
One product, one page, three different units — a monthly rate and two different daily rates. Maximus also carries a June 2026 federal warning letter addressed to its operating company at its own email address.
Maximus is not a paid partner; this link may earn a commission if that changes. Full disclosure.
The page prints a monthly prescription rate. It also prints a daily figure described as "less than" one amount, and a second daily figure described as "under" a different, higher amount. All three describe the same product.
None is reconciled to the others and none states how many days the monthly figure covers. A reader taking the first figure they meet on the page carries away the cheapest daily one.
This site records the monthly rate, because it is the only one of the three with a billing period attached, and its qualifier names the other two so nobody later "corrects" it downward.
The FAQ answers the availability question by naming the single state the product is not available in. That is a more checkable statement than an unqualified fifty-state banner, because it can be falsified by one counterexample.
This row therefore records forty-nine states and does not credit a fifty-state claim. The seller says so itself.
The compounding disclaimer is printed as visible text on the product page rather than in a footer, saying the medications are not approved or evaluated for safety, efficacy or quality by the regulator.
Screening the operating company by name against the regulator's live index returns a letter issued in June 2026. The letter was fetched and read: it is addressed to the company at a named street address and at this seller's own email address, and carries a reference number.
The subject is false or misleading claims, misbranded, telehealth. As everywhere on this site, it is disclosed and never scored — it moves no position on any board.
One thing about this host is worth recording for anyone probing it again: a request for a path that does not exist returns a not-found status with a body larger than either real page fetched here. On this host the byte count says nothing at all, and only the status code separates a real page from a missing one.
Maximus received an FDA warning letter issued June 2026. A warning letter discloses; it does not, on its own, disqualify a provider — see the trade-offs above for what this one concerned.
Auren Rx names both its prescribing group, Wasef Health, and its dispensing pharmacy, VialsRX in Houston, with street addresses and phone numbers, and lets a subscriber pause an auto-refill plan on NAD+, sermorelin, glutathione or GHK-Cu instead of forcing a full cancellation.
Auren Rx is not a paid partner; this link may earn a commission if that changes. Full disclosure.
Visit Auren RxYes, issued in June 2026 against the operating company and addressed to this seller's own email address. It is disclosed here and does not affect any score or position.
The page publishes three different figures for one product — a monthly rate and two different daily rates — and reconciles none of them.
Everywhere except one state, which the seller names in its own FAQ.
No. The product page says as visible text that compounded medications are not approved or evaluated for safety, efficacy or quality by the regulator.
No. A research-use pattern fires once on its terms page, inside boilerplate about permitted use of the website. It is a prescribing telehealth service.
Maximus is not a paid partner; this link may earn a commission if that changes. Full disclosure.